{'52WeekChange': -0.45215756,
 'SandP52WeekChange': 0.0644362,
 'address1': '255 State Street',
 'address2': '9th Floor',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 2.99,
 'askSize': 3000,
 'averageDailyVolume10Day': 646762,
 'averageVolume': 408149,
 'averageVolume10days': 646762,
 'beta': 1.47619,
 'beta3Year': None,
 'bid': 2.92,
 'bidSize': 3000,
 'bookValue': 0.902,
 'category': None,
 'circulatingSupply': None,
 'city': 'Boston',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 3.02,
 'dayLow': 2.92,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -4.189,
 'enterpriseToRevenue': 1.604,
 'enterpriseValue': 81787256,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 3.1551428,
 'fiftyTwoWeekHigh': 6.04,
 'fiftyTwoWeekLow': 1.6,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 42721368,
 'forwardEps': -0.83,
 'forwardPE': -3.5180724,
 'fromCurrency': None,
 'fullTimeEmployees': 114,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.0022200001,
 'heldPercentInstitutions': 0.71823996,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1417996800,
 'lastSplitFactor': '2:1',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/pieris.com',
 'longBusinessSummary': 'Pieris Pharmaceuticals, Inc., a clinical-stage '
                        'biopharmaceutical company, discovers and develops '
                        'anticalin-based drugs in the United States. The '
                        'company develops anticalin proteins that are low '
                        'molecular-weight therapeutic proteins derived from '
                        'lipocalins, which are naturally occurring '
                        'low-molecular weight human proteins found in blood '
                        'plasma and other bodily fluids. Its lead respiratory '
                        'program includes PRS-060, a drug candidate, which is '
                        'in Phase I clinical trial that binds to IL-4Ra for '
                        'the treatment of asthma and other inflammatory '
                        'diseases; and lead immuno-oncology program comprises '
                        'PRS-343, a bispecific protein that is in Phase I '
                        'clinical trial for oncology diseases. The company '
                        'also develops PRS-344, a bispecific '
                        'anticalin-antibody fusion protein that is in '
                        'preclinical stage for oncology diseases; and PRS-080, '
                        'a polyethylene glycol conjugated anticalin protein '
                        'that is in Phase IIa clinical trial to target '
                        'hepcidin for the treatment of functional iron '
                        'deficiency in anemic patients with chronic kidney '
                        'disease or in end-stage renal disease patients '
                        'requiring dialysis, as well as other drugs. It has '
                        'strategic partnerships with Les Laboratoires Servier '
                        'and Institut de Recherches Internationales Servier, '
                        'AstraZeneca AB, and Seattle Genetics Inc.; and '
                        'license agreements with TUM, Enumeral Biomedical '
                        'Holdings, Inc., and Sichuan Kelun-Biotech '
                        'Biopharmaceutical Co. Ltd. The company also has a '
                        'research collaboration with the laboratories of '
                        'University of Pittsburgh. Pieris Pharmaceuticals, '
                        'Inc. was incorporated in 2000 and is headquartered in '
                        'Boston, Massachusetts.',
 'longName': 'Pieris Pharmaceuticals, Inc.',
 'market': 'us_market',
 'marketCap': 152776160,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_1570613',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -21548000,
 'nextFiscalYearEnd': 1640908800,
 'open': 2.97,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '857-246-8998',
 'previousClose': 2.95,
 'priceHint': 4,
 'priceToBook': 3.2372506,
 'priceToSalesTrailing12Months': 2.9959047,
 'profitMargins': -0.36706,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 3.02,
 'regularMarketDayLow': 2.92,
 'regularMarketOpen': 2.97,
 'regularMarketPreviousClose': 2.95,
 'regularMarketPrice': 2.97,
 'regularMarketVolume': 232076,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 52320600,
 'sharesPercentSharesOut': 0.0433,
 'sharesShort': 2263559,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 2035866,
 'shortName': 'Pieris Pharmaceuticals, Inc.',
 'shortPercentOfFloat': 0.0479,
 'shortRatio': 5.94,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'PIRS',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.417,
 'twoHundredDayAverage': 3.0352159,
 'volume': 232076,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.pieris.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02109'}